The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancer DOI Creative Commons

B. Hebert,

James Bradley

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2024, Volume and Issue: 5(6), P. 1365 - 1372

Published: Nov. 26, 2024

There has been a rapid expansion of immunotherapy options for non-small cell lung cancer (NSCLC) over the past two decades, particularly with advent immune checkpoint inhibitors. Despite emerging role in adjuvant and neoadjuvant settings though, relatively few patients will respond to which can be problematic due expense toxicity; thus, development biomarkers capable predicting immunotherapeutic response is imperative. Due promise noninvasive, personalized approach providing comprehensive, real-time monitoring tumor heterogeneity evolution, there wide interest concept using circulating DNA (ctDNA) predict treatment response. Although use ctDNA detect actionable mutations such as EGFR now integral standard care NSCLC, several large studies have also shown its potential biomarker Ongoing interventional clinical trials, BR.36 trial, help clarify therapeutic guidance. this technology, are many limitations considerations that clinicians need aware prior widespread implementation practice, effect underlying comorbidities, fraction, stage malignancy, concordance between aberrations detected tissue.

Language: Английский

Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation DOI Creative Commons
Moawiah M. Naffaa, Ola A Al-Ewaidat, Sopiko Gogia

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: 6

Published: April 27, 2025

Neoantigen-based immunotherapy has emerged as a transformative approach in cancer treatment, offering precision medicine strategies that target tumor-specific antigens derived from genetic, transcriptomic, and proteomic alterations unique to cells. These neoantigens serve highly specific targets for personalized therapies, promising more effective tailored treatments. The aim of this article is explore the advances neoantigen-based highlighting successful treatments such vaccines, tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor-engineered T cells therapy (TCR-T), chimeric antigen receptor (CAR-T), particularly types like glioblastoma (GBM). Advances technologies next-generation sequencing, RNA-based platforms, CRISPR gene editing have accelerated identification validation neoantigens, moving them closer clinical application. Despite results, challenges tumor heterogeneity, immune evasion, resistance mechanisms persist. integration AI-driven tools multi-omic data refined neoantigen discovery, while combination therapies are being developed address issues suppression scalability. Additionally, discusses ongoing development immunotherapies targeting mutations, emphasizing need continued collaboration between computational experimental approaches. Ultimately, cutting-edge research holds potential revolutionize care, hope targeted

Language: Английский

Citations

0
Comparative efficacy of targeted therapies and immunotherapy in advanced non-small cell lung cancer: a systematic review DOI Open Access

Byron Cristobal Llongo Cali,

Jorge Eduardo Paredes Jaramillo,

Jennifer Alicia Álvarez Navas

et al.

International Journal of Research in Medical Sciences, Journal Year: 2024, Volume and Issue: 12(9), P. 3384 - 3393

Published: Aug. 12, 2024

Targeted therapies and immunotherapies revolutionized advanced NSCLC treatment outcomes. exploit specific genetic mutations (e.g., EGFR, ALK, BRAF) to inhibit cancer growth while offering significant benefits in progression-free overall survival. therapy drugs for include osimertinib, gefitinib, erlotinib, alectinib, brigatinib, lorlatinib, ceritinib, dabrafenib, trametinib, crizotinib.Resistance side effects like ILD hepatotoxicity cardiovascular issues remain challenges. Immunotherapies with checkpoint inhibitors PD-1, PD-L1, CTLA-4 enhance the immune system's ability body becomes able combat cancer. Drugs pembrolizumab, nivolumab, atezolizumab have shown good efficacy but immune-related adverse a concern. Combination such as e.g., nivolumab ipilimumab can be better option which concerned because these also show promise enhancing

Language: Английский

Citations

0
The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancer DOI Creative Commons

B. Hebert,

James Bradley

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2024, Volume and Issue: 5(6), P. 1365 - 1372

Published: Nov. 26, 2024

There has been a rapid expansion of immunotherapy options for non-small cell lung cancer (NSCLC) over the past two decades, particularly with advent immune checkpoint inhibitors. Despite emerging role in adjuvant and neoadjuvant settings though, relatively few patients will respond to which can be problematic due expense toxicity; thus, development biomarkers capable predicting immunotherapeutic response is imperative. Due promise noninvasive, personalized approach providing comprehensive, real-time monitoring tumor heterogeneity evolution, there wide interest concept using circulating DNA (ctDNA) predict treatment response. Although use ctDNA detect actionable mutations such as EGFR now integral standard care NSCLC, several large studies have also shown its potential biomarker Ongoing interventional clinical trials, BR.36 trial, help clarify therapeutic guidance. this technology, are many limitations considerations that clinicians need aware prior widespread implementation practice, effect underlying comorbidities, fraction, stage malignancy, concordance between aberrations detected tissue.

Language: Английский

Citations

0